Maternal serum perlecan levels in women with preeclampsia

Akbas M., Koyuncu F. M., ARTUNÇ ÜLKÜMEN B., TANELİ F., Ozdemir H.

Hypertension in Pregnancy, vol.39, no.1, pp.70-76, 2020 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.1080/10641955.2019.1711390
  • Journal Name: Hypertension in Pregnancy
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.70-76
  • Keywords: perlecan, Preeclampsia, severe preeclampsia
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

Objective: Perlecan is an extracellular matrix proteoglycan suggested to maintain endothelial functions. We aimed to measure maternal serum perlecan levels in different preeclampsia phenotypes. Methods: This study included 50 women with preeclampsia and 30 healthy pregnant women. Results: Serum perlecan levels were significantly higher (p = 0.016) in preeclamptic women with severe features(n = 23) than preeclampsia patients(n = 27). There were no statistically significant differences in serum perlecan levels between the early-onset preeclampsia(n = 25), late-onset preeclampsia(n = 25), and healthy pregnancies. Conclusion: Our findings suggest that preeclamptic women with severe features have higher serum perlecan levels than women with preeclampsia.